MCID: DMY004
MIFTS: 53

Demyelinating Disease

Categories: Neuronal diseases

Aliases & Classifications for Demyelinating Disease

MalaCards integrated aliases for Demyelinating Disease:

Name: Demyelinating Disease 12 14
Demyelinating Diseases 52 42 69
Demyelinating Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3213
MeSH 42 D003711
NCIt 47 C34527
ICD10 33 G37.9
UMLS 69 C0011303

Summaries for Demyelinating Disease

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to tumefactive multiple sclerosis and charcot-marie-tooth disease. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Natalizumab and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 72 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Related Diseases for Demyelinating Disease

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
id Related Disease Score Top Affiliating Genes
1 tumefactive multiple sclerosis 30.5 CCL2 CCL3 MMP9 TNF
2 charcot-marie-tooth disease 30.0 IL1B PLP1 TNF
3 lymphoma 29.6 CD40LG IFNG IL17A IL1B TNF
4 carotid artery dissection 28.6 CCL3 CD40LG CXCL10 IFNB1 IFNG IL1B
5 multiple sclerosis, disease progression, modifier of 11.1
6 variola major 11.0 CD40LG MBP
7 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 11.0 IL7R PTPRC
8 chronic duodenal ileus 11.0 CD40LG MBP
9 central pontine myelinolysis 11.0
10 cogan-reese syndrome 11.0 AQP4 IFNB1 MBP
11 balo concentric sclerosis 10.9
12 hypolipoproteinemia 10.9 CD40LG IFNB1 MBP
13 spoan syndrome 10.9 CD40LG IFNB1
14 transmitted_by 10.9 CD40LG CXCL10 MBP
15 malignant eyelid melanoma 10.9 CD40LG CXCL10 IL17A
16 diabetic macular edema 10.9 CD40LG ICAM1 IL17A
17 compensatory emphysema 10.9 CCL2 CD40LG MMP9
18 toxic optic neuropathy 10.8 IL1B MMP9
19 childhood cerebellar astrocytic neoplasm 10.8 CD40LG IL7R PTPRC
20 cytomegalovirus retinitis 10.8 CCL2 ICAM1
21 breast adenomyoepithelioma 10.8 CXCL10 IL1B MMP9
22 hodgkin's lymphoma, nodular sclerosis 10.8 CD40LG ICAM1
23 temporal arteritis 10.8 CD40LG MBP MOG
24 ovarian surface papilloma 10.8 IL1B MBP MOG
25 neuropathy, hereditary sensory and autonomic, type vi 10.8 CCL2 ICAM1 MMP9
26 discitis 10.7 CD40LG TNF TNFRSF1A
27 epileptic encephalopathy, early infantile, 39 10.7
28 ulcerative colitis 10.7 AQP4 MBP TNF
29 ceruminous carcinoma 10.7 CD40LG MBP TNF
30 calciphylaxis 10.7 AQP4 IL1B MMP9
31 lung disease 10.7 CD40LG IL17A TNF
32 peripheral nervous system disease 10.7 CD40LG TNF TNFRSF1A
33 lower urinary tract calculus 10.7 AQP4 CCL2 CXCL10 IL1B
34 alkhurma hemorrhagic fever 10.7 CD40LG IL17A TNF
35 indolent myeloma 10.7 CD40LG IL1B TNF
36 granuloma annulare 10.7 CCL2 CD40LG ICAM1 IL1B
37 leukodystrophy, adult-onset, autosomal dominant 10.7
38 ileocolitis 10.7 CD40LG IL1B TNF
39 urethral intrinsic sphincter deficiency 10.7 CCL2 MMP9 TNF
40 cryptococcosis 10.7 CD40LG IL17A TNF
41 familial mediterranean fever, ad 10.7 IL1B TNF TNFRSF1A
42 megaloblastic anemia 10.7 CD40LG IL1B TNF
43 patau syndrome 10.7 IL1B TNF TNFRSF1A
44 dermatomycosis 10.7 CD40LG ICAM1 TNF
45 testicular infarct 10.7 CD40LG IL1B TNF
46 high pressure neurological syndrome 10.7 CCL2 IL1B TNF
47 foodborne botulism 10.7 CD40LG IL1B TNF
48 human monocytic ehrlichiosis 10.7 CD40LG IL1B TNF
49 choreatic disease 10.6 CD40LG MBP TNF TNFRSF1A
50 pancreas lymphoma 10.6 IL1B TNF TNFRSF1A

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease

Symptoms & Phenotypes for Demyelinating Disease

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG ICAM1 IL17A IL1B TNF TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD40LG ICAM1 IL17A IL1B NTF3 TNF

MGI Mouse Phenotypes related to Demyelinating Disease:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 ABCD1 AQP4 CD40LG CXCL10 ICAM1 IFNB1
2 immune system MP:0005387 10.41 MOG PLP1 PTPRC TNF TNFRSF1A ABCD1
3 homeostasis/metabolism MP:0005376 10.38 ABCD1 AQP4 CD40LG CXCL10 ICAM1 IFNB1
4 cellular MP:0005384 10.33 MBP MMP9 MOG PLP1 PTPRC TNF
5 growth/size/body region MP:0005378 10.29 AQP4 ICAM1 IFNG IL17A MBP MMP9
6 mortality/aging MP:0010768 10.28 PTPRC TNF TNFRSF1A AQP4 CD40LG CXCL10
7 cardiovascular system MP:0005385 10.26 AQP4 CD40LG CXCL10 ICAM1 IFNG IL1B
8 endocrine/exocrine gland MP:0005379 10.22 ABCD1 AQP4 CD40LG ICAM1 IFNG IL17A
9 nervous system MP:0003631 10.22 IL1B MBP MMP9 MOG NTF3 PLP1
10 digestive/alimentary MP:0005381 10.14 AQP4 ICAM1 IFNG IL17A MMP9 PTPRC
11 neoplasm MP:0002006 10.02 ICAM1 IFNB1 IFNG IL1B IL7R MMP9
12 muscle MP:0005369 10.01 TNF TNFRSF1A ICAM1 IFNG MMP9 MOG
13 reproductive system MP:0005389 9.91 MMP9 NTF3 PLP1 TNF TNFRSF1A ABCD1
14 respiratory system MP:0005388 9.76 AQP4 IFNG IL17A MMP9 NTF3 PTPRC
15 skeleton MP:0005390 9.65 CD40LG IFNB1 IFNG IL17A IL1B MMP9
16 vision/eye MP:0005391 9.36 IFNG MBP MMP9 MOG NTF3 PLP1

Drugs & Therapeutics for Demyelinating Disease

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 608)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 189261-10-7
2
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2 504-24-5 1727
9
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
10
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
11
Menthol Approved Phase 4,Phase 1,Early Phase 1 2216-51-5 16666
12
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
13
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 216503-57-0
14
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
15
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
16
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
17
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
18
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
19
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
20
Etanercept Approved, Investigational Phase 4 185243-69-0
21
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 1959-05-2, 59-05-2 126941
22
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
23
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
24
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
25 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
26
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
27
Calcium Carbonate Approved Phase 4 471-34-1
28
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
29
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
30
Ethanol Approved Phase 4,Phase 3 64-17-5 702
31 Peppermint oil Approved Phase 4,Phase 3
32
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
33
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
34
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
35
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
36
Cetirizine Approved Phase 4,Phase 1,Phase 2 83881-51-0 2678
37
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
38
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
39
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
40
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
41
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
42
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
43
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
44
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
45 Piracetam Approved Phase 4 7491-74-9
46
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 50-02-2 5743
48
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Early Phase 1 24280-93-1 446541
50
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 1729)

id Name Status NCT ID Phase Drugs
1 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
2 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
4 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
5 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
6 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
7 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
8 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
9 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
10 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
11 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
12 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
13 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
14 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
15 Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan Completed NCT00503503 Phase 4 Enbrel (etanercept)
16 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
17 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
18 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
19 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
20 Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy Completed NCT00336557 Phase 4
21 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4 extended release fampridine;Placebo
22 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia Completed NCT01556685 Phase 4
23 Rebif® Pregnancy Registry Completed NCT00338741 Phase 4
24 A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® Completed NCT00239993 Phase 4 glatiramer acetate
25 A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy Completed NCT00238654 Phase 4
26 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
27 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
28 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4 IFN-β-1a (Rebif®)
29 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4 Fingolimod;Standard MS DMTs
30 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
31 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
32 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
33 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4 Fingolimod (FTY720)
34 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
35 The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial Completed NCT01034579 Phase 4
36 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
37 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities Completed NCT01456416 Phase 4
38 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4 Fingolimod
39 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
40 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
41 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
42 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
43 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
44 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
45 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4 Interferon beta 1a, oral doxycycline
46 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif;Betaferon/Betaseron
47 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
48 Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment Completed NCT00942214 Phase 4 Natalizumab
49 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
50 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Genetic Tests for Demyelinating Disease

Anatomical Context for Demyelinating Disease

MalaCards organs/tissues related to Demyelinating Disease:

39
Brain, Testes, Bone, T Cells, Spinal Cord, Bone Marrow, B Cells

Publications for Demyelinating Disease

Articles related to Demyelinating Disease:

(show top 50) (show all 173)
id Title Authors Year
1
Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease. ( 28732510 )
2017
2
AhR-deficiency as a cause of demyelinating disease and inflammation. ( 28851966 )
2017
3
DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. ( 28929835 )
2017
4
Vascular hypoperfusion in acute optic neuritis is a potentially new neurovascular model for demyelinating diseases. ( 28926646 )
2017
5
Citation classics in central nervous system inflammatory demyelinating disease. ( 28638708 )
2017
6
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 28535894 )
2017
7
Clinical features in very early-onset demyelinating disease with anti-MOG antibody. ( 28551039 )
2017
8
Demyelinating disease: Astrocyte stress precedes demyelination in cerebral X-ALD. ( 28387337 )
2017
9
Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. ( 28533776 )
2017
10
Treatment of Theiler's virus-induced demyelinating disease with teriflunomide. ( 28913765 )
2017
11
MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. ( 28284341 )
2017
12
Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. ( 28104248 )
2017
13
Recruitment of endogenous CNS stem cells for regeneration in demyelinating disease. ( 28554395 )
2017
14
Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen. ( 28484224 )
2017
15
Prostaglandin E2 produced following infection with Theiler's virus promotes the pathogenesis of demyelinating disease. ( 28445497 )
2017
16
Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. ( 28793252 )
2017
17
NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease. ( 28887429 )
2017
18
The balance between cathepsin C and cystatin F controls remyelination in the brain of Plp1-overexpressing mouse, a chronic demyelinating disease model. ( 28251676 )
2017
19
Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. ( 28495143 )
2017
20
CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. ( 28657431 )
2017
21
The many faces of demyelinating diseases: acute disseminated encephalomyelitis and Guillain-BarrAc syndrome in the same patient. ( 28591395 )
2017
22
Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly. ( 27760861 )
2016
23
An Occult Malignancy Behind a Demyelinating Disease: POEMS Syndrome. ( 27790622 )
2016
24
The role of growth factors as a therapeutic approach to demyelinating disease. ( 27016070 )
2016
25
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification? ( 26846455 )
2016
26
The role of I+4 integrin in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease: an infectious animal model for multiple sclerosis (MS). ( 27803063 )
2016
27
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 27746022 )
2016
28
FLT PET/CT in a Case of Demyelinating Disease. ( 27088385 )
2016
29
Intractable Hiccup in Demyelinating Disease with Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody. ( 27725560 )
2016
30
Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population. ( 26951408 )
2016
31
The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. ( 27519147 )
2016
32
Serum concentration of CD40L is elevated in inflammatory demyelinating diseases. ( 27725124 )
2016
33
Demyelinating disease: Novel markers for disease severity in neuromyelitis optica. ( 27020559 )
2016
34
Germinoma Mimicking Tumefactive Demyelinating Disease in Pediatric Patients. ( 26811911 )
2016
35
Comparison of Cerebrospinal Fluid Opening Pressure in Children With Demyelinating Disease to Children With Primary Intracranial Hypertension. ( 27909013 )
2016
36
Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease. ( 26791341 )
2016
37
Rituximab therapy for ankylosing spondylitis associated to demyelinating disease of the central nervous system. ( 25776441 )
2015
38
A Demyelinating Disease; What Lies Beneath? ( 26204979 )
2015
39
Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease. ( 26385521 )
2015
40
Cerebral adrenoleukodystrophy: a demyelinating disease that leaves the door wide open. ( 26503938 )
2015
41
Methionyl-tRNA Formyltransferase (MTFMT) Deficiency Mimicking Acquired Demyelinating Disease. ( 26060307 )
2015
42
Pain and spinal cord imaging measures in children with demyelinating disease. ( 26509120 )
2015
43
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway. ( 25721871 )
2015
44
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. ( 26496907 )
2015
45
Elevated cerebrospinal fluid opening pressure in a pediatric demyelinating disease cohort. ( 25681000 )
2015
46
Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome? ( 25511890 )
2015
47
Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. ( 26298324 )
2015
48
Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. ( 26409478 )
2015
49
Hypoxia Inducible Factor-1I+ in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease(,.) ( 26213713 )
2015
50
Vitamin D in multiple sclerosis and central nervous system demyelinating disease--a review. ( 25985434 )
2015

Variations for Demyelinating Disease

Expression for Demyelinating Disease

Search GEO for disease gene expression data for Demyelinating Disease.

Pathways for Demyelinating Disease

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CCL2 CCL3 CD40LG CXCL10 ICAM1 IFNB1
2
Show member pathways
13.91 CCL2 CCL3 CD40LG CXCL10 IL17A IL1B
3
Show member pathways
13.74 CCL2 CCL3 CD40LG CXCL10 IFNB1 IFNG
4
Show member pathways
13.61 CCL2 CCL3 ICAM1 IFNB1 IFNG IL17A
5
Show member pathways
13.49 CCL2 CCL3 CD40LG CXCL10 IL17A IL1B
6
Show member pathways
13.37 CCL2 CCL3 CD40LG CXCL10 IL17A IL1B
7
Show member pathways
13.36 CCL2 CCL3 CD40LG CXCL10 ICAM1 IFNB1
8
Show member pathways
12.96 CCL2 CCL3 CXCL10 IFNB1 IFNG IL1B
9
Show member pathways
12.92 CCL2 MMP9 PTPRC TNF TNFRSF1A
10
Show member pathways
12.91 CD40LG ICAM1 IFNG IL17A IL1B TNF
11
Show member pathways
12.89 CCL2 CXCL10 ICAM1 IFNB1 IFNG IL1B
12
Show member pathways
12.77 CXCL10 IFNB1 IFNG IL1B TNF
13
Show member pathways
12.74 CD40LG IL1B NTF3 TNF TNFRSF1A
14
Show member pathways
12.71 CD40LG IFNG IL1B TNF TNFRSF1A
15
Show member pathways
12.68 CD40LG IFNG PTPRC TNF TNFRSF1A
16
Show member pathways
12.64 CCL2 IFNG IL17A IL1B TNF
17
Show member pathways
12.53 CD40LG IFNG IL17A IL1B PTPRC TNF
18 12.52 CCL2 CD40LG CXCL10 IFNG IL17A IL1B
19
Show member pathways
12.43 CCL2 CXCL10 IFNG IL17A IL1B MMP9
20
Show member pathways
12.35 CD40LG IFNG IL1B TNF TNFRSF1A
21 12.32 IFNB1 IFNG IL1B TNF TNFRSF1A
22
Show member pathways
12.28 CXCL10 IFNB1 IFNG IL1B TNF
23
Show member pathways
12.26 IFNB1 IFNG IL17A IL1B TNF
24 12.23 IFNG MMP9 TNF TNFRSF1A
25 12.22 AQP4 IL1B PLP1 TNF
26 12.18 CCL2 ICAM1 IFNG IL1B MMP9 TNF
27 12.16 IFNB1 IFNG IL1B TNF TNFRSF1A
28 12.11 CCL2 ICAM1 IL17A IL1B MMP9 TNF
29 12.06 IFNG IL7R PTPRC TNF
30 12.05 CCL2 CXCL10 ICAM1 IL1B MMP9 TNF
31
Show member pathways
12.02 IFNG IL17A IL1B TNF
32 12.01 CCL3 IFNB1 IFNG IL1B
33 11.99 CD40LG ICAM1 IL1B TNF TNFRSF1A
34 11.98 CCL2 ICAM1 IL1B TNF
35 11.95 IFNB1 IFNG IL7R PTPRC
36
Show member pathways
11.91 CD40LG NTF3 TNF TNFRSF1A
37 11.88 IFNB1 IFNG IL1B IL7R PTPRC TNF
38 11.85 CCL3 IFNG IL1B
39 11.82 CCL2 CCL3 ICAM1 IFNG IL17A IL1B
40
Show member pathways
11.79 CD40LG IFNG TNF
41 11.79 CCL2 CCL3 IL1B MMP9 TNF
42
Show member pathways
11.77 CD40LG TNF TNFRSF1A
43 11.75 CD40LG ICAM1 TNF
44 11.7 CCL3 IFNG IL17A IL1B IL7R PTPRC
45 11.64 CCL2 IFNG IL1B TNF
46 11.62 CD40LG IL7R PTPRC
47 11.62 CCL2 CD40LG ICAM1 IFNG IL1B TNF
48 11.6 IFNG TNF TNFRSF1A
49
Show member pathways
11.59 IFNG TNF TNFRSF1A
50 11.57 ICAM1 MMP9 TNF

GO Terms for Demyelinating Disease

Cellular components related to Demyelinating Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CCL2 CCL3 CD40LG CXCL10 IFNB1 IFNG
2 extracellular space GO:0005615 9.73 CCL2 CCL3 CD40LG CXCL10 ICAM1 IFNB1
3 membrane raft GO:0045121 9.56 ICAM1 PTPRC TNF TNFRSF1A
4 external side of plasma membrane GO:0009897 9.28 AQP4 CD40LG CXCL10 ICAM1 IFNG IL17A

Biological processes related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.99 CXCL10 IFNB1 IFNG PTPRC
2 positive regulation of protein phosphorylation GO:0001934 9.98 IFNG IL1B MMP9 TNF
3 response to lipopolysaccharide GO:0032496 9.98 CCL2 CXCL10 ICAM1 IL1B TNFRSF1A
4 cytokine-mediated signaling pathway GO:0019221 9.96 CCL2 IL1B IL7R TNFRSF1A
5 defense response GO:0006952 9.96 CXCL10 IFNB1 TNF TNFRSF1A
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 CD40LG ICAM1 IL1B TNF
7 response to virus GO:0009615 9.92 CXCL10 IFNB1 IFNG TNF
8 chemokine-mediated signaling pathway GO:0070098 9.9